Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
Xiangyu Yan, Songhan Huang, Yang Yang, Ziwen Lu, Feiyu Li, Liyong Jiang, Yong Jiang, Jun Liu – 15 December 2021 – The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research. Therefore, we performed this systematic review and meta‐analysis to investigate the potential survival benefits of mTOR inhibitors (mTORis).